



Signet 4E3 Monoclonal Antibody for Detection of P-glycoprotein- External Epitope

P-glycoprotein detection is becoming an important tool in the investigation of cancer multidrug resistance (MDR), a phenomenon in which resistance to one drug is associated with resistance to a variety of unrelated drugs.

Signet's 4E3 monoclonal antibody, directed against an external epitope of P-glycoprotein, can be used to determine the level of expression of P-glycoprotein in tissue specimens and on intact, viable cells, providing the advantage of being able to isolate P-glycoprotein positive cells for further studies.

Please call 800-223-0796 for additional information on 4E3 and our other antibodies for investigation of multidrug resistance, C219, C494 and JSB-1.



SIGNET

Signet Laboratories, Inc.


180 Rustcraft Rd., Dedham, MA 02026

Fax: 617-461-2456 Tel: 617-329-7919

800-223-0796

For research use only. Not for use in diagnostic procedures.

Arceci, R.J., et al. A monoclonal antibody to an external epitope of the P-glycoprotein. Proceedings of the American Association for Cancer Research 33:471, 1992.



WE FIND PATHS WHERE
OTHERS FAIL TO LOOK

At the Sandoz Cytokine Development Unit (CDU), we are exploring new paths of research and development and studying more options in disease treatment than were ever thought possible. Using the latest technology, the CDU is working to develop these treatments rapidly, with the same high-quality standards we have always upheld.

At the CDU, our commitment to research and development is unsurpassed. Sandoz created the

CDU as an independent unit, fueled by the dedication of specialized personnel. These highly skilled individuals have been brought together for a common goal—to explore new paths of therapy.



The all-new edition of the unsurpassed resource for the day-to-day management of your patients with cancer.

MEDICAL ONCOLOGY, 2/e

Basic Management and Clinical Management of Cancer

Paul Calabresi, M.D. & Philip S. Schein, M.D.
George P. Canellos, M.D., John H. Glick, M.D., John S. Macdonald, M.D.,
Daniel D. Von Hoff, M.D.

Uniquely designed to meet the needs of the medical oncologists and primary care physician, the all-new Second Edition of **MEDICAL ONCOLOGY** provides you with authoritative review of the basic mechanisms underlying cancer therapy • current single and multimodal treatment approaches • and the theory and practice of supportive and palliative care.


At the core of **MEDICAL ONCOLOGY** is its in-depth survey of specific neoplasms, bringing together information essential at each point in the clinical decision-making process.

Second Edition Highlights Include: Molecular Biology for the Oncologist • Human Retroviruses and Cancer • Oncogenes • Tumor Growth Cell Kinetics and Cancer • Chemotherapy • Tumor Markers • Acute & Chronic Leukemias • Neoplasms of the Lung • Colorectal Cancer • Hematologic Considerations in Cancer • Control of Pain • Neoplasms Associated with AIDS • Cancer and Pregnancy • Office Practice of Oncology • Ethical and Psychosocial Issues in Oncology • Rehabilitation of the Patient with Cancer.

Available May 1993/1344 Pages/650 Illus/
ISBN: 105408-1/\$135.00 (tent.)


"Invaluable"

New England Journal of Medicine



*review of previous edition

Also New From McGraw-Hill



*review of previous edition

THE BASIC SCIENCE OF ONCOLOGY, 2/e


Editors: Ian F. Tannock, M.D.,
Richard P. Hill, Ph.D.

"It Delivers, Bravo."

—Journal of National Cancer Institute

Thoroughly revised and updated, provides you with timely, cohesive, straightforward account of the basic science aspects of clinical oncology.

May 1992/420 Pages/304 Illus/ISBN: 105407-3/\$49.95



BIOLOGICAL APPROACHES TO CANCER TREATMENT Biomodulation

Editor: Malcolm S. Mitchell, M.D.

Unparalleled in depth and breadth of coverage, this groundbreaking work equips you with the tools and materials needed to ultimately devise your own rational approach to biomodulation in cancer therapy.

August 1992/624 Pages/Illus/ISBN: 105397-2/\$95.00

ORDER TODAY FOR YOUR FREE 30 DAY TRIAL!

SPEED YOUR ORDER. CALL TOLL FREE 1-800-262-4729 (Between 8:00a.m. - 4:30p.m. EST)

Please Mention Your Reference # 74SP004



Clip and Mail to:

McGRAW-HILL, INC. Blue Ridge Summit, PA 17214-9989

YES! Please send me the book(s) I've checked on 30 day free trial. After 30 days, I will remit the full price plus local taxes and postage/handling or return the book(s) without obligation.

SAVE MONEY! Pay by check or credit card and McGraw-Hill pays postage. On all orders please add handling charges: \$3.50 on orders over \$40.00, \$2.00 on orders of \$40.00 or less. Other orders will be billed for postage and handling.

☐ Check enclosed: \$ _____ Check No. _____

☐ Charge my order to: ☐ VISA ☐ Master Card* ☐ AMEX

Account No.: _____

Exp. Date: _____ *MC Bank No.: _____

Signature: _____

Date: _____

☐ Bill Me ☐ Bill My Organization

☐ Calabresi: MEDICAL ONCOLOGY, 2/e (105408-1) \$135.00 (tent.)

☐ Mitchell: BIO APPROACHES TO CANCER TREATMENT
(105397-2) \$95.00

☐ Tannock: BASIC SCIENCE OF ONCOLOGY, 2/e (105407-3) \$49.95

Please Print:

Name: _____

Organization: _____

Address: _____

City: _____ State: _____ Zip: _____

Daytime Telephone: _____

Offer only good in U.S. Prices outside the U.S. are slightly higher. All orders subject to acceptance by McGraw-Hill. All prices subject to change without notice. 30-Day Trial does not apply to PreTest Titles. Shipment to P.O. Boxes must be prepaid.

Speed Your Order. Call Toll-Free 1-800-262-4729.

Be sure to mention your reference no.

74SP004

CR

Phosphotyrosine Detection


The Next Generation

RC 20: Recombinant anti-phosphotyrosine PY20 antibody engineered for highest affinity

→ Antibody Fc segment removed

→ mutations resulting in higher affinity incorporated

→ direct conjugation to peroxidase or alkaline phosphatase for ease of detection



Normal human fibroblasts treated with EGF for 0(A) 1(B) 3(C) or 5(D) minutes and subjected to western blot in a 1 step method with RC20H recombinant anti-phosphotyrosine

Now, single step non-radioactive detection on western blots in under 1 hour

Higher sensitivity and lower background than conventional P-tyr antibodies
easy to use protocol included

Affordably priced

In Europe, contact

AFFINITI

Research Products Limited
Telephone: (44) 602 436100
Facsimile: (44) 602 436300

In Japan, contact

FUNAKOSHI CO., LTD.

9-7 Hongo 2-Chome, Bunkyo-Ku,
Tokyo 113, Japan
Telephone: 81-3-5684-1622
Facsimile: 81-3-5684-1633



**Transduction
Laboratories**

Lexington, Kentucky
1-800-227-4063
Phone 606-277-1399
Fax 606-276-2251

Also available

antibodies to map kinases
antibodies to SH2 proteins
antibodies to other signal
transduction proteins

AMERICAN CANCER SOCIETY CLINICAL AWARDS

The American Cancer Society is proud to announce its Clinical Awards for 1994 funding: the Clinical Oncology Fellowship (COF), the Clinical Oncology Career Development Award (CDA), and the Cancer Control Career Development Award for Primary Care Physicians (CCCCA).

The COF is a one-year institutional award intended to support a multidisciplinary training experience for physicians and dentists preparing for a leadership career in academic oncology. The Fellowship is expected to provide unique training in addition to that which is normally provided in postgraduate training programs designed to fulfill requirements of specialty boards. The COF stipend is \$10,000 per year.

The CDA is a three-year award given to promising junior faculty who will pursue academic careers in clinical oncology. A successful application must describe in detail a supervised program that will develop the candidate's clinical expertise and his/her capacity to perform independent clinical/laboratory research. The annual stipend for the CDA is \$25,000 for the first year, and \$30,000 and \$35,000 for the second and third years, respectively.

In order to encourage and support activities in cancer control, the Society offers a limited number of CCCDA's to physicians specializing in primary care. It is anticipated that physicians trained under these two-year grants will improve cancer control through involvement in primary care practice, education, and research activities related to cancer control. These awards are intended to develop academic leaders in primary care specialties emphasizing cancer control.

Please note that candidates for these awards must be citizens or permanent residents of the United States. The application deadlines for each of these awards are as follows:

Clinical Oncology Fellowship:	July 1, 1993
Clinical Oncology Career Development Award:	August 1, 1993
Cancer Control Career Development Award:	August 15, 1993

To request additional information or application materials for these programs, contact the office of:

Virginia Krawiec, M.P.A.
Professional Education Department
American Cancer Society, Inc.
1599 Clifton Road, N.E.
Atlanta, GA 30329-4251
404-329-5734

AMERICAN CANCER SOCIETY

CLINICAL ONCOLOGY FELLOWSHIPS

The American Cancer Society is pleased to announce the 1994 Clinical Oncology Fellowships (COF). The COF is intended to support a multidisciplinary training experience for physicians and dentists preparing for a leadership career in academic oncology. The program may include training in cancer control, prevention, detection, diagnosis, therapy, rehabilitation, and research. The Fellowship is expected to provide unique training in addition to that which is normally provided in postgraduate training programs designed to fulfill requirements of specialty boards, and it is available to citizens or permanent residents of the United States only.

Applications are to be submitted by institutions (not prospective fellows) by July 1, 1993 for fellowships to begin July 1, 1994. The stipend for this one-year award is \$10,000.

To request further information or application materials, please contact the office of:

Virginia Krawiec, M.P.A.
Professional Education Department
American Cancer Society, Inc.
1599 Clifton Road, N.E.
Atlanta, GA 30329-4251
404-329-5734

AMERICAN CANCER SOCIETY

CLINICAL ONCOLOGY CAREER DEVELOPMENT AWARDS

The American Cancer Society is pleased to announce the 1994 Clinical Oncology Career Development Award (CDA). This award is intended to encourage and develop promising candidates who will pursue academic careers in clinical oncology. Through the CDA, the Society seeks to support individuals in supervised programs that will develop the candidate's clinical expertise and his/her capacity to perform independent clinical and/or laboratory research.

These awards are intended to support the early development of careers in academic clinical oncology; thus physicians who already have well established careers with substantial research funding should not apply. In addition, candidates for these awards must be citizens or permanent residents of the United States.

This is a three-year award. The stipend for the award is \$25,000 for the first year, \$30,000 for the second, and \$35,000 for the third. The application deadline is August 1, 1993 for awards to begin July 1, 1994.

To request further information or application materials, please contact the office of:

Virginia Krawiec, M.P.A.
Professional Education Department
American Cancer Society, Inc.
1599 Clifton Road, N.E.
Atlanta, GA 30329-4251
404-329-5734

AMERICAN CANCER SOCIETY

CANCER CONTROL CAREER DEVELOPMENT AWARD FOR PRIMARY CARE PHYSICIANS

The American Cancer Society is pleased to announce the 1994 Cancer Control Career Development Award for Primary Care Physicians (CCCCA). This award is intended to develop academic leaders in primary care specialties emphasizing cancer control: family practice, general internal medicine, obstetrics and gynecology, and pediatrics. Through the CCCCA, the Society seeks to support individuals in supervised programs that will develop the candidate's clinical and teaching expertise and his/her capacity to perform independent clinical research in cancer control. It is anticipated that physicians trained under these awards will improve cancer control through involvement in primary care practice, education, and research activities related to cancer control.


Candidates for first year Cancer Control Career Development Awards for Primary Care Physicians may not have an academic rank above that of Assistant Professor and must not be tenured or be the section head (or equivalent) in his/her discipline. These awards are intended to support the early development of academic careers which place emphasis on cancer control; physicians with well established careers and substantial research funding should not apply. In addition, candidates for these awards must be citizens or permanent residents of the United States.

This is a two-year award. The stipend for the award is \$25,000 for the first year and \$30,000 for the second. The application deadline is August 15, 1993 for awards to begin July 1, 1994.

To request further information or application materials, please contact the office of:

Virginia Krawiec, M.P.A.
Professional Education Department
American Cancer Society, Inc.
1599 Clifton Road, N.E.
Atlanta, GA 30329-4251
404-329-5734

**This publication
is available in
microform.**



University Microfilms
International reproduces this publication
in microform: microfiche and 16mm or 35mm film.
For information about this publication or any of the
more than 13,000 titles we offer, complete and mail
the coupon to: University Microfilms International,
300 N. Zeeb Road, Ann Arbor, MI 48106. Call us
toll-free for an immediate response: 800-521-3044.
Or call collect in Michigan, Alaska and Hawaii:
313-761-4700.

☐ Please send information about these titles:

Name _____

Company/Institution _____

Address _____

City _____

State _____ Zip _____

Phone () _____

**University
Microfilms
International**

**NINTH INTERNATIONAL SYMPOSIUM
ON CELLULAR ENDOCRINOLOGY**

**"Cell Signalling and the Molecular
Stress Response"**

September 23-26, 1993

at

**Whiteface Inn Resort & Club
Lake Placid, NY**

Sponsored By:

W. Alton Jones Cell Science Center, Inc.



ORGANIZING COMMITTEE:

**James L. Stevens, W. Alton Jones Cell Sci. Ctr.
Cecil B. Pickett, Merck Research Laboratories
William F. Greenlee, Purdue University**

Topics include: mechanisms of transcription; protein
kinases; cell cycle and p53; heat shock and glucose
regulated proteins; regulation of cyt P450 and GSH-
transferases; multidrug resistance genes; peroxisome
proliferator, steroid and dioxin receptor mediated effects;
molecular responses to asbestos, UV-light, ionizing
radiation, metals, DNA damage, nitric oxide.

INVITED SPEAKERS

**Patrick A. Baeuerle
Yinon Ben-Neriah
Chris Bradfield
Margaret A. Brostrom
Max Costa
Tom Curran
Albert J. Fornace, Jr.
Mary-Jane Gething
Stephen Green
Oliver Hankinson
Nicholas Heintz
Peter Herrlich
Susan Jaken
Michael Karin**

**Jeff Laskin
Amy S. Lee
John T. Lis
Ian Macara
John McLachlan
Richard I. Morimoto
Brooke Mossman
William B. Pratt
Carol Prives
Danny Reinberg
Dennis J. Thiele
Ralph Weichselbaum
James P. Whitlock, Jr.
Xiao-kun Zhang**

REGISTRATION FORMS MAY BE OBTAINED FROM:

**The Organizing Committee
W. Alton Jones Cell Science Center, Inc.
10 Old Barn Road
Lake Placid, NY 12946
Tel: (518) 523-1252
Fax: (518) 523-1849**